¿ Aastrom Biosciences Inc., of Ann Arbor, Mich., formalized an agreement with Beth Israel Deaconess Medical Center, of Boston, to conduct external clinical beta site evaluations of Aastrom's DC-I dendritic cell product for use in vaccines to treat cancer. The center will conduct the evaluation in conjunction with the Dana-Farber Cancer Institute, of Boston.
¿ Biospecifics Technologies Corp., of Lynbrook, N.Y., said it received a Nasdaq staff determination on April 10 notifying it that its common stock failed to maintain a minimum market value of public float of $5 million, as required by the Nasdaq National Market, and is subject to delisting. Biospecifics will request a hearing before the Nasdaq Listing Qualifications Panel to review the determination.
¿ Maxim Pharmaceuticals Inc., of San Diego, said its product, Ceplene, will be tested in a multinational clinical study expected to start this month. The study, titled "Dynamically Individualized Treatment of Hepatitis C Infection and Correlates of Viral/Host Dynamics," will aim to develop a new treatment strategy for chronic hepatitis C that can increase the sustained viral response to therapy, while minimizing impairment of quality of life and socio-economic burden. Also, Maxim said it expects 72-week data from its completed Phase II study of Ceplene in combination with interferon-alpha will be presented at the European Association for the Study of Liver conference in Prague, Czech Republic, on Friday.
¿ Organogenesis Inc., of Canton, Mass., said its technology business unit submitted three 510(k) marketing applications to the FDA for its engineered collagen products. The business unit was formed in 2000's third quarter to commercialize Organogenesis' engineered collagen and conditioned medium technologies through partnership and distributorship arrangements. Products made from Organogenesis' Fortaflex can be designed to integrate with bordering tissue over time or remain passive in the body.
¿ Samaritan Pharmaceuticals Inc., of Las Vegas, said its subsidiary, Steroidogenesis Inhibitors Inc., and Altachem Pharma Ltd., of Edmonton, Alberta, agreed that both parties will withdraw all remaining claims before The Court of the Queens Bench in Edmonton. The court approved the joint dismissal on Thursday. Separately, the companies agreed to explore a possible joint venture to develop Samaritan's product, Anticort, in the People's Republic of China. One week ago, the court dismissed Altachem's claims against Samaritan relating to attempts by Altachem to acquire worldwide rights to Anticort.